nach oben

Cancer Causes & Control

Erschienen in:

01.10.2014 | Original paper

C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis

verfasst von: Bo Zhou, Bin Shu, Jue Yang, Jing Liu, Tao Xi, Yingying Xing

Erschienen in: Cancer Causes & Control | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many studies have evaluated the associations between pre-diagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6) and colorectal cancer risk, but their results are inconsistent. We therefore conducted a meta-analysis to investigate these associations.

Methods

A comprehensive literature search up to October 2013 was undertaken in PubMed. Pooled relative risk (RR) estimates and 95 % confidence intervals (CIs) were used to calculate estimated effect.

Results

Eighteen studies on CRP comprising a total of 4,706 colorectal cancer cases were included in this meta-analysis. The summary RR of colorectal cancer for one unit change in natural logarithm (ln) CRP was 1.12 [95 % CI (1.05–1.21)]. There was statistically significant heterogeneity among studies (p = 0.006; I ² = 51.7 %). After excluding the studies contributing most to the heterogeneity, summary estimate was essentially unchanged. In addition, the association was significant for colon cancer [RR = 1.13, 95 % CI (1.05–1.21)], not for rectal cancer [RR = 1.03, 95 % CI (0.90–1.17)]. We also found that CRP was significantly associated with increased risk of colorectal cancer among men, but not among women. There were six studies on IL-6 that involved a total of 1,068 colorectal cancer cases. The pooled RR of colorectal cancer for one unit change in ln IL-6 was 1.10 (95 % CI 0.88–1.36), and no statistically significant heterogeneity was found (p = 0.175; I ² = 34.8 %).

Conclusion

Our results suggest that pre-diagnostic circulating CRP is associated with increased risk of colorectal cancer. However, there is no significant association between IL-6 and colorectal cancer risk.

Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30PubMedCrossRef

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCentralPubMedCrossRef

Ullman TA, Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140:1807–1816PubMedCrossRef

Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862PubMedCrossRef

Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E et al (2011) Intestinal cancer risk in Crohn’s disease: a meta-analysis. J Gastrointest Surg 15:576–583PubMedCrossRef

Jess T, Rungoe C, Peyrin-Biroulet L (2012) Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 10:639–645PubMedCrossRef

Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613PubMedCrossRef

Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A et al (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 106:1340–1350PubMedCentralPubMedCrossRef

10.

Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448–454PubMedCrossRef

11.

Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP et al (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123:1133–1140PubMedCrossRef

12.

Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J et al (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15–26PubMedCrossRef

13.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

14.

Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301–1309PubMed

15.

Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6:40–57

16.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

17.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCentralPubMedCrossRef

18.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51(264–269):W264CrossRef

19.

dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW (2010) Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 39:699–709CrossRef

20.

Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N et al (2013) Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case–control study. Am J Epidemiol 177:3–13PubMedCentralPubMedCrossRef

21.

Helzlsouer KJ, Erlinger TP, Platz EA (2006) C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42:704–707PubMedCrossRef

22.

Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE (2010) C-reactive protein and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 102:202–206PubMedCrossRef

23.

Prizment AE, Folsom AR, Dreyfus J, Anderson KE, Visvanathan K et al (2013) Plasma C-reactive protein, genetic risk score, and risk of common cancers in the atherosclerosis risk in communities study. Cancer Causes Control 24:2077–2087PubMedCrossRef

24.

Nozoe T, Matsumata T, Kitamura M, Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176:335–338PubMedCrossRef

25.

Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15:369–373PubMedCrossRef

26.

Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226PubMedCrossRef

27.

Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K et al (2005) Serum IL-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11:1639–1643PubMedCentralPubMedCrossRef

28.

Dymicka-Piekarska V, Matowicka-Karna J, Gryko M, Kemona-Chetnik I, Kemona H (2007) Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 120:585–590PubMedCrossRef

29.

Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH et al (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 97:1266–1270PubMedCentralPubMedCrossRef

30.

Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y et al (2008) Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 98:540–544PubMedCrossRef

31.

Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Kedra B, Lukaszewicz M et al (2008) Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46:1423–1428PubMedCrossRef

32.

Kwon KA, Kim SH, Oh SY, Lee S, Han JY et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10:203PubMedCentralPubMedCrossRef

33.

Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU et al (2011) Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer 104:51–59PubMedCentralPubMedCrossRef

34.

Cooney RV, Chai W, Franke AA, Wilkens LR, Kolonel LN et al (2013) C-reactive protein, lipid-soluble micronutrients, and survival in colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 22:1278–1288PubMedCrossRef

35.

Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585–590PubMedCrossRef

36.

Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M et al (2005) Colorectal cancer and serum C-reactive protein levels: a case–control study nested in the JACC Study. J Epidemiol 15(Suppl 2):S185–S189PubMedCrossRef

37.

Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142:425–432PubMedCrossRef

38.

Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC et al (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14:2413–2418PubMedCrossRef

39.

Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15:381–384PubMedCrossRef

40.

Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC et al (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol 24:5216–5222PubMedCrossRef

41.

Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S et al (2006) Plasma C-reactive protein and risk of colorectal cancer in a nested case–control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 15:690–695PubMedCrossRef

42.

Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S et al (2006) A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66:2483–2487PubMedCrossRef

43.

Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27:2217–2224PubMedCrossRef

44.

Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB et al (2010) Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case–control study within the European prospective investigation into cancer and nutrition. Am J Epidemiol 172:407–418PubMedCrossRef

45.

Chan AT, Ogino S, Giovannucci EL, Fuchs CS (2011) Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140:799–808PubMedCentralPubMedCrossRef

46.

Lee S, Choe JW, Kim HK, Sung J (2011) High-sensitivity C-reactive protein and cancer. J Epidemiol 21:161–168PubMedCentralPubMedCrossRef

47.

Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011) Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 20:297–307PubMedCentralPubMedCrossRef

48.

Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G et al (2011) Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 20:428–437PubMedCentralPubMedCrossRef

49.

Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M et al (2012) Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 72:3029–3037PubMedCentralPubMedCrossRef

50.

Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y et al (2013) Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 132:2648–2658PubMedCentralPubMedCrossRef

51.

Song M, Wu K, Ogino S, Fuchs CS, Giovannucci EL et al (2013) A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer 108:1891–1898PubMedCentralPubMedCrossRef

52.

Wu J, Cai Q, Li H, Cai H, Gao J et al (2013) Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis 34:2799–2803PubMedCentralPubMedCrossRef

53.

Itzkowitz SH, Yio X (2004) Inflammation and cancer IV: colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17PubMedCrossRef

54.

Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS et al (2004) Comparison of risk factors for colon and rectal cancer. Int J Cancer 108:433–442PubMedCentralPubMedCrossRef

55.

Iacopetta B (2002) Are there two sides to colorectal cancer? Int J Cancer 101:403–408PubMedCrossRef

56.

Zhou B, Liu J, Wang ZM, Xi T (2012) C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One 7:e43075PubMedCentralPubMedCrossRef

57.

Green J, Czanner G, Reeves G, Watson J, Wise L et al (2012) Menopausal hormone therapy and risk of gastrointestinal cancer: nested case–control study within a prospective cohort, and meta-analysis. Int J Cancer 130:2387–2396PubMedCrossRef

Titel: C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis
verfasst von: Bo Zhou
Bin Shu
Jue Yang
Jing Liu
Tao Xi
Yingying Xing
Publikationsdatum: 01.10.2014
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 10/2014
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-014-0445-8

Springer Medizin

C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Breast screening: an obsessive compulsive disorder

Maternal consumption of coffee and tea during pregnancy and risk of childhood brain tumors: results from an Australian case–control study

Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis

Maternal reproductive history, fertility treatments and folic acid supplementation in the risk of childhood acute leukemia: the ESTELLE Study

Birthweight, early life body size and adult mammographic density: a review of epidemiologic studies

Sedentary behavior is associated with colorectal adenoma recurrence in men

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie